ASTH Quote, Financials, Valuation and Earnings

biote Corp. has a net margin of 0.11% compared to Astrana Health, Inc.'s net margin of 19.22%. Astrana Health, Inc.'s return on equity of 1.85% beat biote Corp.'s return on equity of --.

Astrana Health, Inc. has a consensus price target of $40.2500, signalling upside risk potential of 74.85%. On the other hand biote Corp. has an analysts' consensus of $4.51 which suggests that it could grow by 74.88%. Given that biote Corp. has higher upside potential than Astrana Health, Inc., analysts believe biote Corp. is more attractive than Astrana Health, Inc..

Astrana Health, Inc. has a beta of 0.862, which suggesting that the stock is 13.753% less volatile than S&P 500. In comparison biote Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astrana Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. biote Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health, Inc. pays -- of its earnings as a dividend. biote Corp. pays out -- of its earnings as a dividend.

Astrana Health, Inc. quarterly revenues are $956M, which are larger than biote Corp. quarterly revenues of $48M. Astrana Health, Inc.'s net income of $1.1M is lower than biote Corp.'s net income of $9.2M. Notably, Astrana Health, Inc.'s price-to-earnings ratio is 121.16x while biote Corp.'s PE ratio is 3.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health, Inc. is 0.39x versus 0.47x for biote Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of 0.11% compared to Astrana Health, Inc.'s net margin of 9.58%. Astrana Health, Inc.'s return on equity of 1.85% beat Cryo-Cell International, Inc.'s return on equity of --.

Astrana Health, Inc. has a consensus price target of $40.2500, signalling upside risk potential of 74.85%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 120.78%. Given that Cryo-Cell International, Inc. has higher upside potential than Astrana Health, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Astrana Health, Inc..

Astrana Health, Inc. has a beta of 0.862, which suggesting that the stock is 13.753% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.089%.

Astrana Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 16.88% to investors and pays a quarterly dividend of $0.15 per share. Astrana Health, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

Astrana Health, Inc. quarterly revenues are $956M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Astrana Health, Inc.'s net income of $1.1M is higher than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Astrana Health, Inc.'s price-to-earnings ratio is 121.16x while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health, Inc. is 0.39x versus 0.98x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners, Inc. has a net margin of 0.11% compared to Astrana Health, Inc.'s net margin of -20.12%. Astrana Health, Inc.'s return on equity of 1.85% beat P3 Health Partners, Inc.'s return on equity of -223.63%.

Astrana Health, Inc. has a consensus price target of $40.2500, signalling upside risk potential of 74.85%. On the other hand P3 Health Partners, Inc. has an analysts' consensus of $10.25 which suggests that it could grow by 82.38%. Given that P3 Health Partners, Inc. has higher upside potential than Astrana Health, Inc., analysts believe P3 Health Partners, Inc. is more attractive than Astrana Health, Inc..

Astrana Health, Inc. has a beta of 0.862, which suggesting that the stock is 13.753% less volatile than S&P 500. In comparison P3 Health Partners, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astrana Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health, Inc. pays -- of its earnings as a dividend. P3 Health Partners, Inc. pays out -- of its earnings as a dividend.

Astrana Health, Inc. quarterly revenues are $956M, which are larger than P3 Health Partners, Inc. quarterly revenues of $345.3M. Astrana Health, Inc.'s net income of $1.1M is higher than P3 Health Partners, Inc.'s net income of -$69.5M. Notably, Astrana Health, Inc.'s price-to-earnings ratio is 121.16x while P3 Health Partners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health, Inc. is 0.39x versus 0.01x for P3 Health Partners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.